novo nordisk semaglutide mash Novo's Wegovy becomes first GLP-1 drug approved for MASH Management and Information |
Description
Simple steps can manage most side effects
Itsbeing studied as a potential treatment for obesity and sarcopenia
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown promising effects on heart failure (HF) outcomes, particularly in phenotype-specific populations
New York, NY October 21, 2024 Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better
In clinical trials, people using GLP-1 drugs lost an average of about 10 pounds more than people using a placebo
